Consensus statement on the management of methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Asia
Journal
Clinical Respiratory Journal
Journal Volume
9
Journal Issue
2
Pages
129-142
Date Issued
2015
Author(s)
Cao B.
Tan T.T.
Poon E.
Kumar S.
Liam C.H.K.
Ahmed K.
Moral P.
Qiu H.
Barez M.Y.
Buntaran L.
Tampubolon O.E.
Thamlikitkul V.
Abstract
Nosocomial pneumonia (NP; encompassing hospital-acquired, health care-associated and ventilator-associated pneumonia) is one of the most common nosocomial infections and is associated with a mortality rate of 18.7%-40.8% in Asian countries. The burden of methicillin-resistant Staphylococcus aureus (MRSA) infections in Asia is high, and approximately 13% of NP cases in Asia are caused by this pathogen. Evidence regarding optimal management of MRSA NP continues to evolve and is complicated by the fact that a significant proportion of cases are likely to be caused by isolates with reduced susceptibility to the main therapeutic agent, vancomycin. The Asian Consensus Taskforce on MRSA Nosocomial Pneumonia has developed this statement to provide consensus points on diagnosis, antimicrobial treatment and prevention strategies for MRSA NP in the Asian context, based on our review of Asian data, previous international guidelines and recent scientific evidence.
SDGs
Publisher
Blackwell Publishing Ltd
Type
journal article